UNIVERSITY OF UTAH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1850-02-28

Employees: 10K

Market Cap: -

Website: http://www.utah.edu

Clinical Trials

Program to Improve Dental Care: Children With ASD

Not Applicable

Terminated

Conditions: Autism

Interventions: Behavioral: Procedure alteration and occupational therapy

First Posted Date: 2018-06-06

Last Posted Date: 2020-11-04

Lead Sponsor: University of Utah

Target Recruit Count: 3

Registration Number: NCT03546504

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia

Early Phase 1

Terminated

Conditions: Infant,Premature
Bronchopulmonary Dysplasia
Pulmonary Hypertension

Interventions: Drug: L-Citrulline

First Posted Date: 2018-05-31

Last Posted Date: 2024-06-10

Lead Sponsor: University of Utah

Target Recruit Count: 16

Registration Number: NCT03542812

Locations: 🇺🇸
University of Utah Health, Salt Lake City, Utah, United States

Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas

Not Applicable

Recruiting

Conditions: Brain Tumor Adult

Interventions: Other: 2HG Spectroscopy Scan
Other: MR Perfusion Scan
Other: Standard of Care Intraoperative MRI

First Posted Date: 2018-05-31

Last Posted Date: 2024-12-09

Lead Sponsor: University of Utah

Target Recruit Count: 60

Registration Number: NCT03542409

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Building Social Skills With Interdisciplinary Process Drama in ASD

Not Applicable

Completed

Conditions: Autistic Disorder

Interventions: Behavioral: Interdisciplinary process drama

First Posted Date: 2018-05-24

Last Posted Date: 2020-08-19

Lead Sponsor: University of Utah

Target Recruit Count: 15

Registration Number: NCT03536351

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

Phase 2

Completed

Conditions: Bladder Cancer
Metastatic Urothelial Carcinoma

Interventions: Drug: Cabozantinib
Drug: Pembrolizumab

First Posted Date: 2018-05-23

Last Posted Date: 2024-11-26

Lead Sponsor: University of Utah

Target Recruit Count: 37

Registration Number: NCT03534804

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Rucaparib in Nonmetastatic prOstAte With BRCAness

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Rucaparib

First Posted Date: 2018-05-23

Last Posted Date: 2024-03-13

Lead Sponsor: University of Utah

Target Recruit Count: 7

Registration Number: NCT03533946

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia

Not Applicable

Terminated

Conditions: Bronchopulmonary Dysplasia
Growth Failure
Infant,Premature

Interventions: Other: No supplemental zinc
Dietary Supplement: Zinc Acetate

First Posted Date: 2018-05-22

Last Posted Date: 2023-05-09

Lead Sponsor: University of Utah

Target Recruit Count: 37

Registration Number: NCT03532555

Locations: 🇺🇸
Intermountain Medical Center, Murray, Utah, United States
🇺🇸
University of Utah Health, Salt Lake City, Utah, United States

Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy

Phase 1

Withdrawn

Conditions: Appendicitis
Pain, Postoperative

Interventions: Drug: Non-narcotic pain control

First Posted Date: 2018-05-17

Last Posted Date: 2020-02-07

Lead Sponsor: University of Utah

Registration Number: NCT03528343

Locations: 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States

Gaze and Postural Stability in Multiple Sclerosis

Not Applicable

Completed

Conditions: Multiple Sclerosis
Dizziness
Vertigo
Falls Injury

Interventions: Behavioral: Gaze and Postural Stability
Behavioral: Standard Care Control

First Posted Date: 2018-05-11

Last Posted Date: 2021-10-06

Lead Sponsor: University of Utah

Target Recruit Count: 42

Registration Number: NCT03521557

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

Early Phase 1

Completed

Conditions: Venous Thromboembolism
Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Drug: Standard heparin dose
Drug: Real time heparin dose adjustment

First Posted Date: 2018-05-04

Last Posted Date: 2023-05-17

Lead Sponsor: University of Utah

Target Recruit Count: 20

Registration Number: NCT03516656

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy